Overview

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Status:
RECRUITING

Trial end date:
2027-10-07

Target enrollment:

Participant gender:

Summary

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Cisplatin
Paclitaxel